熱門資訊> 正文

Lexicon获得Novo第三个1000万美元里程碑

2026-08-24 20:42

Lexicon Pharmaceuticals (LXRX) said it earned a third $10M milestone payment from Novo Nordisk after reaching a patient-dosing milestone in the Phase 1 trial of obesity drug candidate LX9851.
The payment brings Lexicon’s total milestone and upfront proceeds from the collaboration to $75M.
The company is eligible for up to $1 billion, plus royalties on future net sales.

More on Lexicon Pharmaceuticals

Lexicon Pharmaceuticals Edging Closer To 'Go Time' On Multiple Late-Stage Assets
Lexicon Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
Lexicon Pharmaceuticals, Inc. (LXRX) Q2 2026 Earnings Call Transcript
Lexicon anticipates Zynquista NDA resubmission in Q4 2026 as SONATA-HCM top line data expected in Q1 2027
Lexicon Pharmaceuticals GAAP EPS of -$0.07 misses by $0.02, revenue of $28.9M beats by $24.9M

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。